



**BIOLEX, INC. ANNOUNCES FORMATION OF BLUE RIBBON
DEVELOPMENT ADVISORY BOARD**

PITTSBORO, NC, JULY 14, 2003 - Biolex, Inc. today announced the establishment of a Development Advisory Board (DAB) consisting of industry experts in protein manufacturing, process development, clinical and regulatory. Biolex is a private, venture capital-backed biopharmaceutical company located in the Research Triangle region of North Carolina. Biolex possesses a transformational plant-based system for the development of human therapeutic proteins, a large and rapidly growing market. Biolex currently has four top-tier corporate collaborations for seven different proteins. Biolex' corporate partners include Bayer Corporation (2 proteins), Centocor, Inc. (3 proteins), Debiopharm S.A., and a major pharma company.

The Development Advisory Board was constituted to provide the company with the best available outside industry expertise as Biolex moves its pipeline products from Research into Development. The following five eminent industry professionals form the Biolex DAB:

- Carl E. Brooks has held the positions of President and CEO of Cryopharm Corporation and President of the Hyland Division of Baxter International, a fully integrated therapeutic protein business. He is a member of the Board of Directors for Inhibitex, Quantumcor and Bluebird Biosciences. Previously at Baxter, Mr. Brooks advanced from Plant Manager to Engineering Vice President to Executive Vice President of the International Division. Mr. Brooks brings a unique combination of manufacturing, engineering, capital investment planning and general management skills to the Biolex DAB.
- Richard V. McCloskey, M.D., is Vice-President of Medical Research at Centocor, Inc., a wholly owned subsidiary of Johnson & Johnson. Previously, Dr. McCloskey held a series of senior clinical positions at Centocor, Hoffmann La Roche and academia. Dr. McCloskey is Board Certified in Internal Medicine and Infectious Disease. Dr. McCloskey contributes extensive knowledge on drug development in a number of disease areas and practical experience on development of recombinant monoclonal antibodies in particular.
- James E. Pennington, M.D., is Executive Vice President of Medical and Scientific Affairs at InterMune, Inc. Previously, Dr. Pennington held senior clinical positions at Alpha Therapeutics, Shamen Pharmaceuticals, Bayer and academia. He is Board Certified in Internal Medicine and Infectious Disease. Dr. Pennington has designed and supervised the clinical programs in the areas of infectious disease, sepsis, immune disorders, hemophilia, bone marrow transplant and others.

more...





- Kathryn E. Stein, Ph.D., is Vice President for Product Development and Regulatory Affairs at MacroGenics. From 1980 to 2002, Dr. Stein was a member of the Center for Biologics Evaluation and Research (CBER) of the FDA, and Director of the Division of Monoclonal Antibodies from its inception in 1992 until her departure from the FDA in 2002. She was also the key framer of the FDA Guidance document on therapeutic proteins made from transgenic plant systems. Dr. Stein brings to the DAB a wealth of regulatory and practical drug development expertise in therapeutic proteins.
- Mark F. Witcher, Ph.D., has held the positions of Vice President of Manufacturing for MERIX Bioscience, Senior Vice President of Manufacturing Operations for Covance Biotechnology Services (now Diosynth RTP) and Vice President of Manufacturing at Amgen Inc. While at Amgen, Dr. Witcher supervised worldwide scale-up and manufacture of Epogen and Neupogen. Dr. Witcher contributes extensive expertise in state-of-the-art therapeutic protein manufacture under GMP conditions.

“The assembled group of experts has unparalleled practical experience with all facets of protein drug development and manufacturing,” said David Spencer, COO and Vice President of R&D at Biolex. “Along with the extensive background of our own management team, access to the DAB will ensure Biolex’ ability to execute on its strategy, conveying a crucial competitive advantage.”

The foundation of Biolex' technology is its proprietary Lemna Expression System™, coupling the ideal natural characteristics of the green aquatic plant, *Lemna*, with advanced genetic engineering and protein recovery methods. The Lemna Expression System™ uniquely combines the most desired qualities of mammalian cell culture, the current gold standard among existing expression systems (clonal replication, fast growth, high protein content, secretion of the target protein into the media, a contained and controlled environment), with the most sought after characteristics in next generation systems (speed of scale-up, significantly reduced capital requirement, low operating costs).

Biolex, Inc. is a biopharmaceutical company devoted to discovering, developing and commercializing its proprietary advanced protein expression technology for the development of human therapeutics. Biolex' strategy focuses on the development of Biolex proteins as well as those obtained from partner companies. In addition to its unique technology, Biolex has the added advantage of a solid, seasoned management team with extensive industry experience with therapeutic proteins. The Company's headquarters and laboratory facility are based in Pittsboro, North Carolina. Visit the Company's web site at www.biolex.com, where more extensive biographies of the Development Advisory Board members, as well as the management, can be viewed.

CONTACT: John Irick, Senior Vice President, Corporate and Business Development, Biolex, Inc. 919-542-9901.

###



158 Credle Street
Pittsboro, NC 27312
www.biolex.com

tel 919.542.9901
fax 919.542.9910